Vivus Inc Inventory Turnover Ratio (COS)

Cost of Sales Formula, Quarterly Results, Trends, Rankings, Statistics

Due to inventory build up in the first quarter 2020, Vivus Inc's inventory turnover ratio sequentially decreased to 0.5 in the first quarter 2020, unsurprisingly, as the Vivus Inc markets continue to deteriorate, and VVUS's faces growing challenges to bring down its inventories. Vivus Inc's average inventory processing period in the Mar 31 2020 quarter, has increased to 730 days, from 676 days, in the Dec 31 2019 quarter.

Within Healthcare sector 399 other companies have achieved higher inventory turnover ratio. While Inventory turnover ratio total ranking has improved so far during the I Quarter 2020, to 2111, from total ranking in the fourth quarter 2019 at 2117.

VVUS Inventory Turnover Ratio using Sales Formula
What is Inventory Turnover Ratio?
What is Vivus Inc Market Share?

What is Inventory Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Inventory Turnover▼

None ▼

Inventory Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

VVUS Inventory Turnover Ratio	(Mar 31 2020) I. Quarter	(Dec 31 2019) IV. Quarter	(Sep 30 2019) III. Quarter	(Jun 30 2019) II. Quarter	(Mar 31 2019) I. Quarter
Y / Y Inventory Growth	54.63 %	45.59 %	38.91 %	35.28 %	4.47 %
Y / Y Cost of Sales Growth	7.4 %	-22.03 %	-13.43 %	33.2 %	58.32 %
Inventory Turnover Ratio (TTM)	0.5	0.54	0.64	0.71	0.73
VVUS's Total Ranking	# 2111	# 2117	# 2116	# 2134	# 1769
Average inventory processing period	729	674	572	512	502
Seq. Inventory Growth	0.76 %	12.23 %	-0.34 %	37.2 %	-5.13 %
Seq. Cost of Sales Growth	16.55 %	31.63 %	-31.09 %	1.6 %	-15.4 %

Inventory Turnover Ratio Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 136
Healthcare Sector	# 400
Overall Market	# 2111

Inventory Turnover Ratio Statistics
High	Average	Low
2.55	0.81	0
(Mar 31 2016)		(Sep 30 2012)

VVUS Company Profile >> Back to VVUS Efficiency Comparisons >> Compare VVUS Inventory Turnover Ratio to its Competitors

Financial Statements
Vivus Inc's Inventories	$ 34 Millions	Visit VVUS's Balance sheet
Vivus Inc's Cost of Revenues TTM	$ 16 Millions	Visit VVUS's Income Statement
What are VVUS's Sales?		Visit VVUS's Sales by Segment

Other Inventory Turnover Ratios
Vivus Inc's Inventory to Sales Ratio
U.S. Durable Goods Inventory to Shipment Ratio By Product
Major Pharmaceutical Preparations Industry Inventory Turnover Trends and Statistics
Healthcare Sector Inventory Turnover Statistics
Inventory Turnover Trends for overall market
VVUS's Inventory Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Inventory Turnover
Lowest Ranking Inventory Turnover
Inventory Turnover for VVUS's Competitors
Inventory Turnover Ratio for VVUS's Suppliers
Inventory Turnover Ratio for VVUS's Customers

You may also want to know
VVUS's Sales Growth Rates	VVUS's Pe Price to earnings ratio	VVUS's Receivables Turnover Ratio	VVUS's Stock Quote
VVUS's Net Income Growth Rates	VVUS's Ps Price to Sales ratio	VVUS's Sales per Employee	VVUS's Asset Turnover Ratio
VVUS's Net Margin	VVUS's Pb Price to Book ratio	VVUS's Financial Strength Ratios	VVUS's Dividend Payout Ratio

Companies with similar Inventory Turnover Ratio for the quarter ending Mar 31 2020, within Healthcare Sector	Inventory Turnover Ratio	Cost of revenues at quarter ending Mar 31 2020	Inventories at quarter ending Mar 31 2020
Establishment Labs Holdings Inc	1.28	$ 34.181 Millions	$ 27 Millions
Intelgenx Technologies Corp	1.27	$ 0.478 Millions	$ 0 Millions
Halozyme Therapeutics Inc	1.24	$ 46.684 Millions	$ 38 Millions
Seaspine Holdings Corporation	1.23	$ 58.212 Millions	$ 47 Millions
Clearpoint Neuro Inc	1.23	$ 3.864 Millions	$ 3 Millions
Pfizer Inc	1.23	$ 10,164.000 Millions	$ 8,290 Millions
Penumbra Inc	1.22	$ 180.232 Millions	$ 148 Millions
Akebia Therapeutics Inc	1.22	$ 141.792 Millions	$ 117 Millions
Durect Corp	1.21	$ 4.239 Millions	$ 3 Millions
Evolus Inc	1.21	$ 12.233 Millions	$ 10 Millions
Sanuwave Health Inc	1.20	$ 0.534 Millions	$ 0 Millions
Kindred Biosciences Inc	1.20	$ 4.072 Millions	$ 3 Millions
United Therapeutics Corporation	1.19	$ 111.900 Millions	$ 94 Millions
Ani Pharmaceuticals Inc	1.18	$ 57.038 Millions	$ 48 Millions
Clovis Oncology inc	1.17	$ 31.617 Millions	$ 27 Millions
Corcept Therapeutics Inc	1.16	$ 6.142 Millions	$ 5 Millions
Axonics Inc	1.14	$ 15.837 Millions	$ 14 Millions
Acorda Therapeutics Inc	1.13	$ 29.893 Millions	$ 27 Millions
Insmed Inc	1.11	$ 28.500 Millions	$ 26 Millions
Adma Biologics Inc	1.11	$ 46.928 Millions	$ 42 Millions
Coherus Oncology inc	1.08	$ 10.282 Millions	$ 10 Millions
Alphatec Holdings Inc	1.07	$ 36.930 Millions	$ 35 Millions
Viveve Medical Inc	1.04	$ 4.739 Millions	$ 5 Millions
Guided Therapeutics Inc	1.03	$ 0.069 Millions	$ 0 Millions
Optinose Inc	1.02	$ 4.556 Millions	$ 4 Millions
Nuvasive Inc	1.00	$ 309.728 Millions	$ 311 Millions
Titan Pharmaceuticals Inc	0.99	$ 1.155 Millions	$ 1 Millions
Delcath Systems Inc	0.98	$ 0.701 Millions	$ 1 Millions
Globus Medical Inc	0.98	$ 187.001 Millions	$ 191 Millions
Travere Therapeutics Inc	0.97	$ 5.587 Millions	$ 6 Millions

Date modified: 2026-09-02T20:16:03+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.